Najahi-Missaoui W - Search Results

1

Liposomes in Cancer Therapy: How Did We Start and Where Are We Now.

Fulton MD, Najahi-Missaoui W. Fulton MD, et al. Among authors: najahi missaoui w. Int J Mol Sci. 2023 Apr 1;24(7):6615. doi: 10.3390/ijms24076615. Int J Mol Sci. 2023. PMID: 37047585 Free PMC article. Review.

2

Liposomes Targeting P21 Activated Kinase-1 (PAK-1) and Selective for Secretory Phospholipase A₂ (sPLA₂) Decrease Cell Viability and Induce Apoptosis in Metastatic Triple-Negative Breast Cancer Cells.

Najahi-Missaoui W, Quach ND, Somanath PR, Cummings BS. Najahi-Missaoui W, et al. Int J Mol Sci. 2020 Dec 10;21(24):9396. doi: 10.3390/ijms21249396. Int J Mol Sci. 2020. PMID: 33321758 Free PMC article.

3

Safe Nanoparticles: Are We There Yet?

Najahi-Missaoui W, Arnold RD, Cummings BS. Najahi-Missaoui W, et al. Int J Mol Sci. 2020 Dec 31;22(1):385. doi: 10.3390/ijms22010385. Int J Mol Sci. 2020. PMID: 33396561 Free PMC article. Review.

4

Lyophilization of Nanoparticles, Does It Really Work? Overview of the Current Status and Challenges.

Gatto MS, Najahi-Missaoui W. Gatto MS, et al. Among authors: najahi missaoui w. Int J Mol Sci. 2023 Sep 13;24(18):14041. doi: 10.3390/ijms241814041. Int J Mol Sci. 2023. PMID: 37762348 Free PMC article. Review.

5

Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A₂ suppress prostate cancer growth and metastasis.

Verma A, Najahi-Missaoui W, Cummings BS, Somanath PR. Verma A, et al. Among authors: najahi missaoui w. Oncol Lett. 2020 Nov;20(5):179. doi: 10.3892/ol.2020.12040. Epub 2020 Aug 31. Oncol Lett. 2020. PMID: 32934746 Free PMC article.

6

Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion.

Najahi-Missaoui W, Quach ND, Jenkins A, Dabke I, Somanath PR, Cummings BS. Najahi-Missaoui W, et al. Pharmacol Res Perspect. 2019 Sep 6;7(5):e00518. doi: 10.1002/prp2.518. eCollection 2019 Oct. Pharmacol Res Perspect. 2019. PMID: 31516713 Free PMC article.

7

Insight into the function of active site residues in the catalytic mechanism of human ferrochelatase.

Medlock AE, Najahi-Missaoui W, Shiferaw MT, Albetel AN, Lanzilotta WN, Dailey HA. Medlock AE, et al. Among authors: najahi missaoui w. Biochem J. 2021 Sep 17;478(17):3239-3252. doi: 10.1042/BCJ20210460. Biochem J. 2021. PMID: 34402499 Free PMC article.

8

Production and characterization of erythropoietic protoporphyric heterodimeric ferrochelatases.

Najahi-Missaoui W, Dailey HA. Najahi-Missaoui W, et al. Blood. 2005 Aug 1;106(3):1098-104. doi: 10.1182/blood-2004-12-4661. Epub 2005 Apr 14. Blood. 2005. PMID: 15831704 Free PMC article.

9

Altered orientation of active site residues in variants of human ferrochelatase. Evidence for a hydrogen bond network involved in catalysis.

Dailey HA, Wu CK, Horanyi P, Medlock AE, Najahi-Missaoui W, Burden AE, Dailey TA, Rose J. Dailey HA, et al. Among authors: najahi missaoui w. Biochemistry. 2007 Jul 10;46(27):7973-9. doi: 10.1021/bi700151f. Epub 2007 Jun 14. Biochemistry. 2007. PMID: 17567154 Free PMC article.

10

Identification and characterization of solvent-filled channels in human ferrochelatase.

Medlock AE, Najahi-Missaoui W, Ross TA, Dailey TA, Burch J, O'Brien JR, Lanzilotta WN, Dailey HA. Medlock AE, et al. Among authors: najahi missaoui w. Biochemistry. 2012 Jul 10;51(27):5422-33. doi: 10.1021/bi300598g. Epub 2012 Jun 28. Biochemistry. 2012. PMID: 22712763 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters